Attached files
| file | filename |
|---|---|
| EX-99.4 - EXHIBIT 99.4 - Jaguar Health, Inc. | tm2019077d5_ex99-4.htm |
| EX-99.3 - EXHIBIT 99.3 - Jaguar Health, Inc. | tm2019077d5_ex99-3.htm |
| EX-99.1 - EXHIBIT 99.1 - Jaguar Health, Inc. | tm2019077d5_ex99-1.htm |
| EX-10.2 - EXHIBIT 10.2 - Jaguar Health, Inc. | tm2019077d5_ex10-2.htm |
| EX-10.1 - EXHIBIT 10.1 - Jaguar Health, Inc. | tm2019077d5_ex10-1.htm |
| EX-4.1 - EXHIBIT 4.1 - Jaguar Health, Inc. | tm2019077d5_ex4-1.htm |
| 8-K - FORM 8-K - Jaguar Health, Inc. | tm2019077-5_8k.htm |
Exhibit 99.2
May 22, 2020
DTC, Voluntary Reorg Department
Re: Jaguar Health, Inc. Series 2 Warrants (CUSIP: 47010C 128)
Ladies and Gentlemen:
Please be advised that, effective May 22, 2020, pursuant to Section 5(l) of the Series 2 Common Stock Purchase Warrants of Jaguar Health, Inc. (the “Series 2 Warrants”), the Exercise Price for the Series 2 Warrants has been adjusted to $0.49 per share of common stock, par value $0.0001 per share (“Common Stock”). Please note that all exercises resulting in fractions are to be, at the Company’s election, either settled with a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price or rounded up to the next whole share.
[Signature Page Follows]
Jaguar Health, Inc. • 201 Mission Street, Suite 2375 • San Francisco, CA 94105
Tel: +1 (415) 371-8300 • Fax: +1 (415) 371-8311 • https://jaguar.health
| Sincerely, | ||
| JAGUAR HEALTH, INC. | ||
| By: | /s/ Lisa A. Conte | |
| Lisa A. Conte | ||
| President and Chief Executive Officer | ||
RECEIVED AND ACKNOWLEDGED:
American Stock Transfer & Trust Company, LLC
| By: | ||
| Name: | ||
| Title: | ||
[SIGNATURE PAGE TO COMPANY ORDER TO WARRANT AGENT]